biOasis Technologies makes siRNA breakthrough; InVivo Therapeutics Holdings details terms of IPO;

> Biomaterials company InVivo Therapeutics Holdings, focused on treating spinal cord injuries, announced the pricing and quantity of shares to be offered in its planned $14 million share offering. Release

> Central nervous system disease specialist biOasis Technologies says it has discovered a peptide vector that delivers siRNA into brain cells. Release

> The FDA approved Kinex Pharmaceuticals IND for an oral form of the cancer medication irinotecan. More